Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience

N. Vaguliene, M. Zemaitis, V. Sarauskas, A. Vitkauskiene, S. Miliauskas, R. Sakalauskas (Kaunas, Lithuania)

Source: Annual Congress 2012 - New biomarkers for lung cancer
Session: New biomarkers for lung cancer
Session type: Thematic Poster Session
Number: 4214
Disease area: Thoracic oncology

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
N. Vaguliene, M. Zemaitis, V. Sarauskas, A. Vitkauskiene, S. Miliauskas, R. Sakalauskas (Kaunas, Lithuania). Epidermal growth factor receptor mutation status in advanced non-small cell lung cancer: A single institution experience. Eur Respir J 2012; 40: Suppl. 56, 4214

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009


The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer
Source: Eur Respir Rev 2010 19: 186-196
Year: 2010



A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008




Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer
Source: Eur Respir J 2005; 25: 329-335
Year: 2005



Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006

A prospective phase II study of gefitinib for chemo-naïve patients with advanced non-small cell lung cancer with epidermal growth factor receptor gene mutations
Source: Annual Congress 2006 - Lung cancer treatment
Year: 2006


Screening for activating EGFR mutations in surgically resected nonsmall cell lung cancer
Source: Eur Respir J 2011; 38: 903-910
Year: 2011



The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004

Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 183-193
Year: 2011



Epidermal growth factor receptor (EGFR) expression in non-small cell lung carcinoma (NSCLC) and survival
Source: International Congress 2015 – Lung cancer: prognostic factors and features of oncogene-driven tumours
Year: 2015


Nationwide real-world cohort study of first line TKI treatment in epidermal growth factor receptor mutated non-small cell lung cancer.
Source: Virtual Congress 2020 – Real-world data and registries of thoracic oncology
Year: 2020


Prognostic significance of epidermal growth factor receptor expression in nonsmall cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002

Epithelial growth factor receptor (EGFR) mutation status and the treatment of non-small cell lung cancer (NSCLC): A population based quality assurance analysis
Source: International Congress 2015 – Quality management in lung cancer
Year: 2015


Efficacy of Afatinib, Erlotinib, and Gefitinib on epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer (NSCLC) patients with brain metastasis: a network meta-analysis
Source: International Congress 2018 – Lung cancer: modern therapies and beyond
Year: 2018

Epidermal growth factor receptor and related biomarkers evaluated by immunohistochemistry in patients with resected non-small cell lung cancer
Source: Annual Congress 2013 –Prognostic factors and subtyping of lung cancer
Year: 2013


Vascular endothelial growth factor in sera of patients with non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 330s
Year: 2005

Detection of epidermal growth factor receptor mutation in plasma as predictor of gefitinib response in non small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008



Vascular endothelial growth factor C is a predictor of early recurrence and poor prognosis of resected stage I non-small cell lung cancer in Taiwan
Source: Annual Congress 2010 - Prognostic factors for lung cancer
Year: 2010

Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019


Targeting gene of insulin-like growth factor type I (IGF-I) on in vitro model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 387s
Year: 2006